Do you want to link to this Amgen Site outside the UK and leave amgeninflammation.co.uk?
YOU ARE NOW LEAVING THIS WEBSITE. Amgen Limited and Amgen Ireland Limited takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.
Dendritic cells (DCs), a class of bone marrow-derived cells found in the blood, tissues, and lymphoid organs, are antigen presenting cells that serve as a conduit between the innate and adaptive immune systems.1,2 DCs recognize and respond to pathogen-associated molecular patterns capable of initiating an acute inflammatory reaction. Furthermore, they process extracellular and intracellular proteins to present antigens to prime naïve T cells. The three major classes of DCs are pDC, myeloid cDC1, and myeloid cDC2.2
DCs possess a characteristic shape and motility, like no other blood cell, and these features complement their function of capturing antigens and selecting antigen-specific T cells. DCs can stimulate both B and T lymphocytes. Having their presence in most tissues, DCs capture and process antigens and display large amounts of MHC-peptide complexes at their surface. After upregulating their costimulatory molecules and migration to lymphoid organs (spleen and lymph nodes), DCs collaborate and activate antigen-specific T cells.1 Through their maturation process, DCs also upregulate surface proteins, such as CD80, CD86, and CD40, which are critical for T-cell activation and response and synthesize high levels of IL-12 that enhance both innate and acquired immunity.1,2
DCs serve as a potential target in many clinical scenarios that involve T cells, such as transplantation, tumors, immunodeficiency, and vaccines.1 DC dysfunction is known to contribute to the development of infectious diseases, cancer, allergy, and autoimmune disease.1,2
cDC1: type 1 conventional DC; cDC2: type 2 conventional DC; CD: cluster of differentiation; IL: interleukin; MHC: major histocompatibility complex; pDC: plasmacytoid DC.
Adverse events should be reported. Reporting forms and information can be found for the UK at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store, or for Ireland at https://www.hpra.ie/homepage/about-us/report-an-issue. Adverse events and product complaints should also be reported to Amgen Limited on +44 (0)1223 436441 (UK and Northern Ireland) or Freephone 1800 535 160 (Ireland)